GC
SYNH

Guggenheim Capital’s Syneos Health, Inc. Class A Common Stock SYNH Stock Holding History

Guggenheim Capital’s Portfolio SYNH Stock Details SYNH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-64,434
Closed -$2.72M – 1935
2023
Q2 		$2.72M Buy
64,434
+10,409
+19% +$421K 0.02% 734
2023
Q1 		$1.92M Sell
54,025
-15,977
-23% -$580K 0.02% 861
2022
Q4 		$2.57M Buy
70,002
+18,804
+37% +$743K 0.02% 762
2022
Q3 		$2.41M Buy
51,198
+852
+2% +$55K 0.02% 770
2022
Q2 		$3.61M Buy
50,346
+602
+1% +$44K 0.03% 672
2022
Q1 		$4.03M Buy
49,744
+5,644
+13% +$477K 0.02% 739
2021
Q4 		$4.53M Sell
44,100
-12,083
-22% -$1.16M 0.02% 719
2021
Q3 		$4.92M Sell
56,183
-30,049
-35% -$2.72M 0.03% 668
2021
Q2 		$7.72M Buy
86,232
+16,538
+24% +$1.4M 0.05% 490
2021
Q1 		$5.29M Sell
69,694
-3,584
-5% -$270K 0.03% 605
2020
Q4 		$4.99M Sell
73,278
-4,175
-5% -$260K 0.03% 576
2020
Q3 		$4.12M Sell
77,453
-8,359
-10% -$498K 0.03% 607
2020
Q2 		$5M Buy
85,812
+8,392
+11% +$451K 0.04% 518
2020
Q1 		$3.05M Sell
77,420
-11,630
-13% -$680K 0.03% 636
2019
Q4 		$5.3M Sell
89,050
-31,479
-26% -$1.69M 0.04% 602
2019
Q3 		$6.41M Sell
120,529
-6,891
-5% -$354K 0.05% 474
2019
Q2 		$6.51M Sell
127,420
-13,850
-10% -$645K 0.05% 466
2019
Q1 		$7.31M Buy
141,270
+70,471
+100% +$3.42M 0.06% 416
2018
Q4 		$2.79M Sell
70,799
-87,154
-55% -$4.05M 0.02% 874
2018
Q3 		$8.14M Buy
157,953
+69,383
+78% +$3.4M 0.05% 450
2018
Q2 		$4.16M Sell
88,570
-11,717
-12% -$485K 0.03% 828
2018
Q1 		$3.56M Sell
100,287
-234
-0.2% -$9.16K 0.01% 1226
2017
Q4 		$4.38M Sell
100,521
-204,640
-67% -$9.56M 0.01% 1109
2017
Q3 		$16M Buy
305,161
+68,269
+29% +$3.81M 0.04% 558
2017
Q2 		$13.9M Buy
236,892
+167,547
+242% +$8.71M 0.04% 572
2017
Q1 		$3.18M Buy
69,345
+8,667
+14% +$431K 0.01% 1301
2016
Q4 		$3.19M Sell
60,678
-19,831
-25% -$960K 0.01% 1300
2016
Q3 		$3.59M Sell
80,509
-2,303
-3% -$99.9K 0.01% 1216
2016
Q2 		$3.16M Buy
82,812
+3,410
+4% +$150K 0.01% 1265
2016
Q1 		$3.27M Buy
79,402
+66,448
+513% +$2.74M 0.01% 1243
2015
Q4 		$628K Buy
+12,954
New +$576K ﹤0.01% 2327

Other funds holding SYNH

Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Natixis Advisors
Natixis Advisors Boston, Massachusetts $71.9B AUM 28.03% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Nomura Asset Management
Nomura Asset Management Tokyo, Japan $38.8B AUM 30.94% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
CFB
Cullen/Frost Bankers San Antonio, Texas $8.81B AUM 22.47% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Guggenheim Capital's SYNH Position: Q3 2023 in Review

Guggenheim Capital sold out of Syneos Health, Inc. Class A Common Stock (SYNH) in Q3 2023, closing a stake of 64,434 shares — an estimated $2.72M sold.

Guggenheim Capital first reported a position in SYNH in Q4 2015 and held it in 31 quarters. The position peaked at $16M in Q3 2017. 10 funds tracked by Wall St. Rank hold SYNH as of Q3 2023.

  • Guggenheim Capital reported no remaining Syneos Health, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Guggenheim Capital sold 64,434 Syneos Health, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.72M.
  • Guggenheim Capital first reported a position in Syneos Health, Inc. Class A Common Stock in Q4 2015 and held it in 31 quarters.
  • Guggenheim Capital's Syneos Health, Inc. Class A Common Stock position peaked at $16M in Q3 2017.
  • 10 funds tracked by Wall St. Rank held Syneos Health, Inc. Class A Common Stock as of Q3 2023.

Based on Guggenheim Capital's 13F filing for Q3 2023, filed 14 Nov 2023.